TWIST BIOSCIENCE CORP (TWST)
US90184D1000 - Common Stock
Overall TWST gets a fundamental rating of 4 out of 10. We evaluated TWST against 565 industry peers in the Biotechnology industry. TWST has a great financial health rating, but its profitability evaluates not so good. TWST is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TWST has reported negative net income.
TWST had a negative operating cash flow in the past year.
In the past 5 years TWST always reported negative net income.
TWST had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -33.98%, TWST is in the better half of the industry, outperforming 63.81% of the companies in the same industry.
TWST's Return On Equity of -44.16% is fine compared to the rest of the industry. TWST outperforms 71.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.98% | ||
| ROE | -44.16% | ||
| ROIC | N/A |
ROA(3y)-27.66%
ROA(5y)-27.95%
ROE(3y)-34.86%
ROE(5y)-34.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TWST's Gross Margin of 42.61% is fine compared to the rest of the industry. TWST outperforms 77.54% of its industry peers.
In the last couple of years the Gross Margin of TWST has grown nicely.
TWST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.61% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.92%
GM growth 5Y27.06%
2. Health
2.1 Basic Checks
TWST does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TWST has more shares outstanding
The number of shares outstanding for TWST has been increased compared to 5 years ago.
There is no outstanding debt for TWST. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 7.75 indicates that TWST is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 7.75, TWST belongs to the best of the industry, outperforming 84.14% of the companies in the same industry.
There is no outstanding debt for TWST. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.75 |
ROIC/WACCN/A
WACC10.43%
2.3 Liquidity
A Current Ratio of 4.88 indicates that TWST has no problem at all paying its short term obligations.
TWST's Current ratio of 4.88 is in line compared to the rest of the industry. TWST outperforms 53.12% of its industry peers.
TWST has a Quick Ratio of 4.54. This indicates that TWST is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of TWST (4.54) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.88 | ||
| Quick Ratio | 4.54 |
3. Growth
3.1 Past
TWST shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.82%.
The Revenue has grown by 27.69% in the past year. This is a very strong growth!
The Revenue has been growing by 41.90% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-6.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.16%
Revenue 1Y (TTM)27.69%
Revenue growth 3Y33.24%
Revenue growth 5Y41.9%
Sales Q2Q%26.53%
3.2 Future
Based on estimates for the next years, TWST will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.70% on average per year.
The Revenue is expected to grow by 19.82% on average over the next years. This is quite good.
EPS Next Y31.15%
EPS Next 2Y22.46%
EPS Next 3Y14.65%
EPS Next 5Y13.7%
Revenue Next Year19.52%
Revenue Next 2Y19.84%
Revenue Next 3Y18.41%
Revenue Next 5Y19.82%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
TWST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TWST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TWST's earnings are expected to grow with 14.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.46%
EPS Next 3Y14.65%
5. Dividend
5.1 Amount
No dividends for TWST!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TWIST BIOSCIENCE CORP
NASDAQ:TWST (11/22/2024, 8:10:10 PM)
After market: 42 -0.23 (-0.54%)42.23
+0.57 (+1.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.51B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.98% | ||
| ROE | -44.16% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.61% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.88 | ||
| Quick Ratio | 4.54 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-6.82%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y31.15%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)27.69%
Revenue growth 3Y33.24%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y